Last reviewed · How we verify
NCT05606523: EXTRA
Microbiota and Pancreatic Cancer Cachexia
trial in Pancreatic Cancer in 24 participants. Currently enrolling.
30 April 2025
Quick facts
| Lead sponsor | Genton Graf Laurence |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 24 |
| Start date | 1 August 2022 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across Switzerland |
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Microbiota — all drugs for Microbiota →
- Cachexia — all drugs for Cachexia →
Sponsor
Genton Graf Laurence
Who can join
18 and older, any sex, with Pancreatic Cancer or Microbiota. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This monocentric study aims at evaluating the effects of fecal microbiota transplantation from newly diagnosed cachectic and non-cachectic pancreatic cancer patients, and healthy volunteers on several cachexia-related parameters of germ-free mice.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies.
Marroncini G, Naldi L, Martinelli S, Amedei A. · · 2024 · cited 24× · PMID 39061972 · DOI 10.3390/biomedicines12071398 -
Modulating the Gut-Muscle Axis: Increasing SCFA-Producing Gut Microbiota Commensals and Decreasing Endotoxin Production to Mitigate Cancer Cachexia.
Roy S, Alizadeh Bahmani AH, Davids M, Herrema H, et al · · 2025 · cited 5× · PMID 40572244 · DOI 10.3390/microorganisms13061356
Verify or expand the search:
- PubMed search for NCT05606523
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05606523 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Genton Graf Laurence
- Last refreshed: 6 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05606523.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing